Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Patients with PsA, Cutaneous Psoriasis May Undergo Hip Replacement

Richard Quinn  |  July 15, 2016

A recent study of patients with psoriatic arthritis and cutaneous psoriasis found that these patients do not have a higher risk of worse outcomes after total hip arthroplasty compared with patients with osteoarthritis…

Filed under:ConditionsOther Rheumatic ConditionsPsoriatic ArthritisResearch Rheum Tagged with:Arthritis & Rheumatologyhiphip arthroplastyhip replacementPsoriasisPsoriatic Arthritis

Family History Biggest Predictor of Heart Attacks in People with Psoriasis

Lisa Rapaport  |  July 2, 2016

(Reuters Health)—People with psoriasis, a chronic inflammatory disease, are more likely to have heart attacks and strokes when they have a family history of cardiovascular problems, a Danish study suggests. Psoriasis wasn’t associated with higher risk of heart attacks or strokes when people with the skin condition didn’t have a family history of cardiovascular disease,…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:cardiovascularheartPsoriasis

Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 13, 2016

Etanercept Submitted for Chronic, Severe Plaque Psoriasis in Children The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for etanercept (Enbrel) for treating pediatric patients with chronic, severe plaque psoriasis.1 The application was submitted in early January 2016 and is based on results of a one-year Phase 3 study with…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPediatric Conditions Tagged with:ApprovalsBiologicsBiosimilarsclinical trialsdrugetanerceptFDAknee painOsteoarthritisPediatricplaquePsoriasisrheumatologySafety

Long-Term Therapy with Lilly Drug Found to Help Plaque Psoriasis

Gene Emery  |  June 8, 2016

NEW YORK (Reuters Health)—Aggregated results from three studies of patients with moderate to severe plaque psoriasis show that Eli Lilly’s injectable drug ixekizumab can completely resolve the plaques in about one third of cases after 12 weeks of treatment. And with continued therapy every four weeks, at least half maintained or attained complete resolution of…

Filed under:Drug Updates Tagged with:clinical trialsixekizumabplaque psoriasis

Etanercept Submitted to FDA for Approval to Treat Pediatric Plaque Psoriasis; Boehringer Ingelheim & AbbVie to Collaborate; Low Doses of Gerilimzumab Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  April 13, 2016

The FDA has received an application to expand the use of etanercept to treat plaque psoriasis in pediatric patients. Boehringer Ingelheim and AbbVie have announced a collaborative partnership to develop treatments for multiple autoimmune diseases. And gerilimzumab may prove safe and effective for treating inflammatory diseases at very low doses…

Filed under:Biologics/DMARDsDrug Updates Tagged with:etanerceptgerilimzumabInflammatory Diseasemonoclonal antibodyplaque psoriasisRheumatoid Arthritis (RA)

U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis

Reuters Staff  |  March 25, 2016

(Reuters)—U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co. to treat adults with moderate to severe cases of plaque psoriasis. The injectable drug known chemically as ixekizumab will be sold under the brand name Taltz, the U.S. Food and Drug Administration said. Taltz works by blocking interleukein-17A, a…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug Administrationixekizumabplaque psoriasisskin

Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity

Michele B. Kaufman, PharmD, BCGP  |  March 23, 2016

In a 52-week clinical trial, patients with plaque psoriasis who took secukinumab achieved greater sustained skin clearance then those taking ustekinumab. Also, three clinical trials showed ixekizumab improves work productivity in patients with plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:ixekizumabplaque psoriasisproductivitysecukinumabskinustekinumabworkplace

Psoriasis Drug Succeeds in Mid-Stage Study

Reuters Staff  |  March 17, 2016

(Reuters)—Drug developer Vitae Pharmaceuticals Inc. said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up 70% in after-hours trading. Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Psoriasissecukinumabskin

Tofacitinib Shows Ongoing Action Against Plaque Psoriasis

David Douglas  |  March 3, 2016

NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) shows long-term efficacy against chronic plaque psoriasis, according to findings from two randomized studies and an extension trial. The outcome, Dr. Svitlana Tatulych told Reuters Health by email, “demonstrated that oral tofacitinib, at both the 10 mg and 5 mg twice-daily doses, provided sustained…

Filed under:Drug Updates Tagged with:Janus Kinase Inhibitorsplaque psoriasisTofacitinib

Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 3, 2016

An etanercept biosimilar referencing Enbrel and designed to treat multiple autoimmune diseases has been approved for the European market. Also, an application for subcutaneous brodalumab to treat plaque psoriasis has been submitted to the FDA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsbrodalumabetanerceptEuropean UnionFDAFood and Drug Administration

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences